Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 4

1(14.3%)

Phase 3

1(14.3%)

7Total

N/A(5)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03936361Phase 3Recruiting

Statins In Intracerbral Hemorrhage

Role: collaborator

NCT06170450Not ApplicableActive Not Recruiting

Cyclic Versus Continuous Sacral Neuromodulation for LUTS

Role: collaborator

NCT04661813Not ApplicableCompleted

Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV

Role: collaborator

NCT03370016Not ApplicableCompleted

The Impact of Low Pressure Pneumo in RARP

Role: lead

NCT04394676Not ApplicableUnknown

The Impact of Low Pressure Pneumo in RARP II

Role: lead

NCT02786173Completed

Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"

Role: lead

NCT03133312Phase 4Completed

Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery

Role: lead

NCT03004222Not ApplicableCompleted

A Study to Determine the Effectiveness of Utilizing Intraperitoneal Bupivacaine

Role: lead

All 8 trials loaded